ProSense® is a liquid nitrogen (LN2) based cryoablation system with a powerful, compact, and user-friendly design for maximum efficacy in breast tumor destruction.
How does
it work?
IceCure’s ProSense Cryoablation System utilizes liquid nitrogen to generate ultra-cold temperatures quickly to create large lethal zones for maximum efficacy in tumor destruction.
Guided by CT or ultrasound, a cryoprobe is inserted into the tumor. A freeze-thaw-freeze cycle destroys the targeted tissue, which becomes necrotic debris eventually absorbed by the body over time – without the need to excise the tumor.
PROSENSE® ADVANTAGES
Clinically proven
Cost effective in-office treatment
Short treatment time for fibroadenomas –
only 5-15 minutes
Touch-screen console
Choice of probes for
customized treatment
(small disposable
component)
Low pressure, safe,
convenient and easy to
use
Painless with immediate return to daily activities
FDA cleared
and CE marked
ICE3
ICE3 is the largest controlled multilocation clinical trial ever performed for liquid nitrogen (LN2) – based cryoablation of small, low-risk, early-stage malignant breast tumors without subsequently removing them. The trial began in 2014 and has completed recruitment of 206 patients in 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel.
CLINICAL SUPPORT
The ProSense™ system is considered an optimal solution for treating breast tumors.
Fibroadenomas
ProSense is FDA-cleared and has successfully been treating fibroadenomas since clinical trials began in 2012.
“The FDA has approved the use of cryoablation as a safe and effective therapy for fibroadenomas.”
American Society of Breast Surgeon’s (ASBrS) Consensus Statement for Management of Fibroadenomas of the Breast
ICE3 Trial
ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them.
96.91%
of trial participants did not have recurrence as of interim analysis performed in July 2022.
“Cryoablation offers an exciting, minimally invasive option to open surgery in the treatment of small, early-stage breast cancer tumors. The innovative Liquid Nitrogen (LN2) based ProSense® System provides more efficient, targeted treatment to completely destroy the tumor in a quick, office-based procedure”
Professor Eisuke Fukuma, MD, PhD, Chairman of Breast Center, Kameda Medical Center, Japan
